A detailed history of Aqr Capital Management LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 8,350 shares of KRYS stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,350
Previous 7,587 10.06%
Holding current value
$1.34 Million
Previous $1.39 Million 8.97%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$174.7 - $213.66 $133,296 - $163,022
763 Added 10.06%
8,350 $1.52 Million
Q2 2024

Aug 14, 2024

BUY
$153.12 - $183.64 $237,489 - $284,825
1,551 Added 25.7%
7,587 $1.39 Million
Q1 2024

May 15, 2024

BUY
$108.01 - $179.35 $187,289 - $310,992
1,734 Added 40.31%
6,036 $1.07 Million
Q4 2023

Feb 14, 2024

BUY
$96.0 - $128.29 $27,648 - $36,947
288 Added 7.17%
4,302 $533,000
Q3 2023

Nov 14, 2023

SELL
$108.51 - $130.22 $47,418 - $56,906
-437 Reduced 9.82%
4,014 $465,000
Q2 2023

Aug 14, 2023

BUY
$78.48 - $130.32 $39,789 - $66,072
507 Added 12.85%
4,451 $522,000
Q1 2023

May 15, 2023

BUY
$72.39 - $84.27 $17,084 - $19,887
236 Added 6.36%
3,944 $315,000
Q4 2022

Feb 14, 2023

BUY
$63.14 - $79.9 $234,123 - $296,269
3,708 New
3,708 $293,000
Q3 2020

Nov 16, 2020

SELL
$37.76 - $48.49 $316,315 - $406,200
-8,377 Closed
0 $0
Q2 2020

Aug 17, 2020

SELL
$37.03 - $60.0 $145,157 - $235,200
-3,920 Reduced 31.88%
8,377 $347,000
Q1 2020

May 15, 2020

BUY
$35.02 - $65.64 $85,728 - $160,686
2,448 Added 24.86%
12,297 $532,000
Q4 2019

Feb 14, 2020

SELL
$33.17 - $65.23 $22,588 - $44,421
-681 Reduced 6.47%
9,849 $545,000
Q3 2019

Nov 14, 2019

BUY
$34.72 - $51.3 $50,621 - $74,795
1,458 Added 16.07%
10,530 $366,000
Q2 2019

Aug 14, 2019

BUY
$27.2 - $41.2 $246,758 - $373,766
9,072 New
9,072 $365,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.13B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.